X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
solvent-based paclitaxel (63) 63
nab-paclitaxel (49) 49
oncology (48) 48
index medicus (46) 46
humans (40) 40
albumin-bound paclitaxel (35) 35
chemotherapy (32) 32
female (26) 26
phase-iii trial (25) 25
1st-line therapy (21) 21
paclitaxel - therapeutic use (20) 20
cremophor-free (19) 19
paclitaxel (19) 19
cancer (18) 18
albumins - therapeutic use (17) 17
aged (16) 16
paclitaxel - administration & dosage (16) 16
treatment outcome (16) 16
lung neoplasms - drug therapy (15) 15
male (15) 15
middle aged (15) 15
carcinoma, non-small-cell lung - drug therapy (14) 14
pharmacology & pharmacy (14) 14
adult (13) 13
breast-cancer (12) 12
cell lung-cancer (12) 12
combination (12) 12
survival (12) 12
albumins - administration & dosage (11) 11
antimitotic agents (11) 11
antineoplastic agents (11) 11
breast cancer (11) 11
elderly-patients (11) 11
albumins - adverse effects (10) 10
animals (10) 10
antineoplastic combined chemotherapy protocols - therapeutic use (10) 10
carboplatin (10) 10
hematology, oncology and palliative medicine (10) 10
metastatic breast-cancer (10) 10
paclitaxel - adverse effects (10) 10
antineoplastic agents, phytogenic - therapeutic use (9) 9
clinical trials (9) 9
phase-ii trial (9) 9
solid tumors (9) 9
taxanes (9) 9
antineoplastic combined chemotherapy protocols - adverse effects (8) 8
breast neoplasms - drug therapy (8) 8
carcinoma, non-small-cell lung - pathology (8) 8
disease-free survival (8) 8
docetaxel (8) 8
drug therapy (8) 8
lung neoplasms - pathology (8) 8
nanoparticles (8) 8
pharmacokinetics (8) 8
aged, 80 and over (7) 7
antineoplastic agents, phytogenic - administration & dosage (7) 7
care and treatment (7) 7
efficacy (7) 7
hematology (7) 7
lung cancer (7) 7
neoplasms - drug therapy (7) 7
neoplasms. tumors. oncology. including cancer and carcinogens (7) 7
patients (7) 7
1st-line chemotherapy (6) 6
antineoplastic agents - administration & dosage (6) 6
antineoplastic agents - therapeutic use (6) 6
antitumor-activity (6) 6
carboplatin - administration & dosage (6) 6
carboplatin - therapeutic use (6) 6
lung cancer, non-small cell (6) 6
medicine & public health (6) 6
metastasis (6) 6
neoplasm staging (6) 6
non-small cell lung cancer (6) 6
non-small-cell lung cancer (6) 6
pancreatic cancer (6) 6
peripheral neuropathy (6) 6
plus carboplatin (6) 6
review (6) 6
safety (6) 6
weekly nab-paclitaxel (6) 6
albumin (5) 5
histology (5) 5
iii trial (5) 5
nanomedicine (5) 5
nanotechnology (5) 5
neutropenia (5) 5
original (5) 5
studies (5) 5
tumors (5) 5
abraxane (4) 4
antineoplastic agents - adverse effects (4) 4
antineoplastic agents, phytogenic - adverse effects (4) 4
biotechnology & applied microbiology (4) 4
breast neoplasms - pathology (4) 4
cancer research (4) 4
cancer therapies (4) 4
carboplatin - adverse effects (4) 4
carcinoma, non-small-cell lung - mortality (4) 4
clinical trials as topic (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 10/2015, Volume 76, Issue 4, pp. 699 - 712
nab-paclitaxel demonstrates improved clinical efficacy compared with conventional Cremophor EL (CrEL)-paclitaxel in multiple tumor types. This study explored... 
Cremophor EL | Medicine & Public Health | Nanoparticle | Albumin | Oncology | Cancer Research | Taxane | Pharmacology/Toxicology | nab -paclitaxel | nab-paclitaxel | COLONY-STIMULATING FACTOR | SOLID TUMORS | PANCREATIC-CANCER | NONLINEAR PHARMACOKINETICS | PHASE-III TRIAL | BREAST-CANCER | ONCOLOGY | ENDOTHELIAL-CELLS | IN-VIVO | PHARMACOLOGY & PHARMACY | SOLVENT-BASED PACLITAXEL | CREMOPHOR EL MICELLES | Endothelium, Vascular - cytology | Paclitaxel - metabolism | Pancreatic Neoplasms - metabolism | Human Umbilical Vein Endothelial Cells - metabolism | Nanoparticles - chemistry | Humans | Capillary Permeability - drug effects | Endothelium, Vascular - drug effects | Paclitaxel - pharmacokinetics | Endosomes - metabolism | Serum Albumin, Human | Drug Delivery Systems | Pancreatic Neoplasms - drug therapy | Tissue Distribution | Antineoplastic Agents, Phytogenic - administration & dosage | Human Umbilical Vein Endothelial Cells - cytology | Endosomes - drug effects | Tubulin Modulators - administration & dosage | Tubulin Modulators - metabolism | Antineoplastic Agents, Phytogenic - metabolism | Biological Transport - drug effects | Antineoplastic Agents, Phytogenic - therapeutic use | Carcinoma - pathology | Paclitaxel - administration & dosage | Serum Albumin - chemistry | Antineoplastic Agents, Phytogenic - pharmacokinetics | Carcinoma - drug therapy | Human Umbilical Vein Endothelial Cells - drug effects | Microinjections | Tubulin Modulators - pharmacokinetics | Pancreatic Neoplasms - pathology | Cells, Cultured | Endosomes - pathology | Paclitaxel - therapeutic use | Tubulin Modulators - therapeutic use | Xenograft Model Antitumor Assays | Animals | Endothelium, Vascular - metabolism | Mice, Nude | Cell Line, Tumor | Endothelium, Vascular - pathology | Carcinoma - metabolism | Infusions, Intravenous | Serum Albumin - metabolism | Antimitotic agents | Dimethyl sulfoxide | Exhibitions | Permeability | Antineoplastic agents | Tumors | Index Medicus | Original
Journal Article
Pediatric Blood & Cancer, ISSN 1545-5009, 07/2015, Volume 62, Issue 7, pp. 1214 - 1221
Journal Article
Journal Article
Cancer Science, ISSN 1347-9032, 07/2014, Volume 105, Issue 7, pp. 812 - 817
Journal Article
Journal Article
Investigational New Drugs, ISSN 0167-6997, 2/2018, Volume 36, Issue 1, pp. 45 - 52
Journal Article
Frontiers in oncology, ISSN 2234-943X, 2014, Volume 4, pp. 300 - 300
[This corrects the article on p. 177 in vol. 4, PMID: 25101242.]. 
Nab-Paclitaxel | Non-small cell lung carcinoma | pemetrexed | Histology | Metastatic | Solvent-based paclitaxel
Journal Article
Journal Article
Journal Article
Journal Article
Annals of Oncology, ISSN 0923-7534, 09/2013, Volume 24, Issue 9, pp. 2390 - 2396
This analysis compared the efficacy and safety outcomes by histology of nab-paclitaxel (nab-P) plus carboplatin (C) versus solvent-based paclitaxel (sb-P) plus... 
Non-small-cell lung cancer | Histology | Nab-paclitaxel | PHASE-III TRIAL | histology | ONCOLOGY | BEVACIZUMAB | ALBUMIN-BOUND PACLITAXEL | nab-paclitaxel | PLUS CARBOPLATIN | ABI-007 | SOLVENT-BASED PACLITAXEL | CHEMOTHERAPY | non-small-cell lung cancer | Carcinoma, Large Cell - drug therapy | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Carcinoma, Large Cell - mortality | Carboplatin - adverse effects | Albumins - therapeutic use | Albumins - adverse effects | Carboplatin - therapeutic use | Neoplasm Metastasis - drug therapy | Neoplasms, Squamous Cell - drug therapy | Aged, 80 and over | Adult | Female | Paclitaxel - blood | Antineoplastic Agents, Phytogenic - therapeutic use | Antineoplastic Agents, Phytogenic - adverse effects | Carcinoma, Non-Small-Cell Lung - pathology | Neoplasms, Squamous Cell - mortality | Paclitaxel - adverse effects | Survival Rate | Treatment Outcome | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Paclitaxel - therapeutic use | Survival | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Organoplatinum Compounds - therapeutic use | Organoplatinum Compounds - adverse effects | Adenocarcinoma - mortality | Index Medicus
Journal Article
Journal Article